<DOC>
	<DOCNO>NCT00001873</DOCNO>
	<brief_summary>Cancers blood , sometimes refer hematologic malignancy , disorder bone marrow cell lead failure normal function bone marrow uncontrolled growth cancerous cell bone marrow . These cancerous cell spill bloodstream affect organ cause widespread symptom . The disease life threaten block normal function marrow , produce red cell ( prevent anemia ) , white cell ( prevent infection ) , platelet ( prevent progression ) . Bone marrow transplant potential form therapy patient hematologic malignancy . However , BMT complicate procedure associate dangerous side effect . In study researcher attempt find way reduce complication BMT , would possible use safely offer patient . In order , researcher develop new technique make BMT safer . It require make small change standard procedure , may improve outcome . The experimental procedure researcher evaluate : 1 . &lt; TAB &gt; T-cell deplete peripheral blood progenitor cell ( PBPC ) transplantation 2 . &lt; TAB &gt; Cyclosporine give immediately transplant 3 . &lt; TAB &gt; Add-back donor lymphocytes Patients undergoing experimental technique must monitor closely see benefit harmful effect occur . Information gather study use develop research study potential new therapy hematologic malignancy .</brief_summary>
	<brief_title>The Role Cyclosporine Blood Cell Transplants With T-Cell Add-Back Blood Cancers</brief_title>
	<detailed_description>Bone marrow stem cell transplant study carry NHLBI BMT Unit focus approach optimize stem cell lymphocyte dose order improve transplant survival increase graft-vs.-leukemia effect . A CD34 stem cell dose great 3 x 10 ( 6 ) /kg find increase survival reduce relapse , CD3+ lymphocyte dose less 1 x 10 ( 5 ) /kg associate low incidence GVHD . Although process 2 peripheral blood progenitor cell ( PBPC ) collection CellPro immunoabsorption method ( combine CD34-positive selection CD2-negative selection ) provide improvement previous method , system always achieve optimal cell dos . A recent preclinical evaluation Department Transfusion Medicine new immunomagnetic cell selection system available Nexell , Inc. demonstrate improved recovery CD34+ cell increase depletion T lymphocytes , compare CellPro method . Incorporation Nexell system ( Isolex 300i ) clinical protocol allow u consistently achieve CD34+ cell dose threshold 3 x 10 ( 6 ) /kg CD3+ lymphocyte dose region 0.5 x 10 ( 5 ) /kg . This make possible test ( 1 ) potential benefit optimize transplant cell dos , ( 2 ) elimination post transplant immunosuppression enhance immune recovery . In study , use Nexell Isolex 300i system obtain data relationship CD34+ stem cell dose outcome . In recipient receive T cell dose less 0.5 x 10 ( 5 ) CD3+ cells/kg effect withdraw cyclosporine development GVHD evaluate cohort study : 20 patient receive low dose cyclosporine . If incidence grade II bad GVHD 10 % less , post transplant immunosuppression give next cohort incidence severity acute GVHD assess . Stopping rule unacceptable GVHD severity apply . Two match group HLA 6/6 5/6 donor-recipient pair separately study use approach . In second phase study continue accumulate data T lymphocyte add-back give day 45 day 100 transplant . For phase , cyclosporine reintroduce day 44 continue day 120 accelerate immune recovery . Up 70 patient age 10 55 year study subset ( HLA 6/6 5/6 matched cohort ) . The major endpoint study acute GVHD transplant . We also measure engraftment , acute chronic GVHD , leukemic relapse , transplant-related cause mortality , cytomegalovirus reactivation leukemia-free survival . Patients follow minimum 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA Patient : Ages 1055 year . Chronic myelogenous leukemia , category : chronic phase , accelerate phase blast transformation . Acute lymphoblastic leukemia , category : Adults ( great 18 year ) first remission highrisk feature ( present leukocyte count great 100,000/cu mm , karyotypes t9 ; 22 , t4 , t11 , biphenotypic leukemia ) All second subsequent remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome , category : refractory anemia transfusion dependence , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia . Myeloproliferative disorder ( myelofibrosis , polycythemia vera , essential thrombocythemia ) transformation acute leukemia . Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000 / mcl ) anemia ( less equal 10g/dl ) due recent chemotherapy . No major organ dysfunction preclude transplantation . DLCO great equal 60 % predict . Left ventricular ejection fraction : great equal 40 % predict . ECOG performance status 0 1 . For adult : Written inform consent give adult . For minor : Written inform consent one parent guardian . Informed oral consent minor : The process explain minor level complexity appropriate age ability comprehend . Women childbearing age negative pregnancy test may participate . EXCLUSION CRITERIA Recipient ( follow ) : Patient pregnant . Age le 10 great 55 year . ECOG performance status 2 . Severe psychiatric illness patient donor . Mental deficiency sufficiently severe make compliance treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival transplant . DLCO le 60 % predict . Left ventricular ejection fraction : le 40 % predict . Serum creatinine great 3mg/dl . Serum bilirubin great 4 mg/dl . Transaminases great 3x upper limit normal . HIV positive ( donor recipient ) . History malignancy except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow . Individuals disease list eligible protocol , debility age make risk intensive myeloablative therapy unacceptable . These patient consider nonmyeloablative allogeneic transplantation protocol ( 97H0202 , 99H0050 ) . INCLUSION CRITERIA Donor : HLA 6/6 identical 5/6 ( one antigen mismatch ) family donor . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) . For adult : Written inform consent give adult . For minor : Written inform consent one parent guardian . Informed oral consent minor : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA Donor ( follow ) : Pregnant lactating . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 8, 2016</verification_date>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Cyclosphosphamide</keyword>
	<keyword>Whole Body Irradiation</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Leukemic Relapse</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Graft-Versus-Myeloma</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>